Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid TumorsBenzinga • 05/18/21
Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus' Anti-TIGIT Bispecific Antibody ProgramGlobeNewsWire • 05/18/21
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody ProgramBusiness Wire • 05/18/21
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerGlobeNewsWire • 04/19/21
Agenus Inc. (AGEN) CEO Garo Armen on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/15/21